Day: April 11, 2024

$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026The Central Bank of Iceland, Financial Supervision has approved Oculis’s prospectus related to the admission of its ordinary shares to trade on the Nasdaq Iceland Main Market; Oculis will announce the first day of trading with at least one day advance noticeOn-track to report topline data from OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED) in Q2 2024ZUG, Switzerland, April 11, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the “Company”), today announced that on April 11, 2024 it completed a financing of approximately $59 million, consisting of the issuance of 5,000,000 of its ordinary shares, nominal value CHF 0.01 per share (the...

CALGARY, Alberta, April 11, 2024 (GLOBE NEWSWIRE) — Acceleware Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of transformative technologies targeting the decarbonization of industrial heating, is pleased to announce that it has been awarded Phase 2 of a potash ore drying project by the International Minerals Innovation Institute (IMII). The new project phase will advance Phase 1 work and is intended to further validate the use of radio frequency (RF) energy from Acceleware’s Clean Tech Inverter (CTI) to dry potash ore and other minerals. IMII is a non-profit organization jointly funded by industry and government that is committed to developing and implementing innovative education, training, research and development partnerships for supporting a world-class minerals industry. IMII’s minerals industry members...

In 2023, the consolidated revenue of the Group of Panevezio statybos trestas AB amounted to 119.828 mln. Euros, whereas in 2022 the consolidated revenue was 115.84 mln. Euros. Over the reporting period, the net profit of the Group amounted to 3.322 mln. Euros and in 2022 the Group had the net profit in the amount of 0.525 mln. Euros.Over the year of 2023, the turnover of Panevezio statybos trestas AB amounted to 80.751 mln. Euros, and in 2022 the turnover of Panevezio statybos trestas AB was 79.222 mln. Euros. In 2023, Panevezio statybos trestas AB has suffered the net loss in the amount of 2.279 mln. Euros, the net loss in 2022 was 1.720 mln. Euros. More information:Managing DirectorTomas StukasTel.: +370 618 21360

TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. (“AutoMax”), a leading vehicle importer company in Israel. According to the Agreement, the Company will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into AutoMax (the “Acquisition”). Following the Acquisition, it is contemplated that SciSparc shareholders will hold together approximately 50.01% of the share capital of the post-closing combined company (the “Combined Company”). The Acquisition...

FREMONT, Calif., April 11, 2024 (GLOBE NEWSWIRE) — Complete Solaria, Inc. (“Complete Solaria” or the “Company”) (Nasdaq: CSLR) today reported on its current financial status, which includes progress on its cash burn rate, and the status of its debt with private equity firms Kline-Hill Partners and Carlyle, which together hold about $70 million in debt owed on about $35 million of principal, split roughly equally between the two (see our 10K for exact numbers). First, we report on our progress in turning Complete Solaria (CSLR) around financially, starting with our dramatic headcount reduction from 428 to 109 (-74.5%) in seven rounds of layoffs.These layoffs were very unfortunate, but necessary for survival. And when any company keeps only the top 25% of its employees, it winds up with an excellent workforce. Yesterday, our board...

The annual conference for U.S. and international special operations forces is expected to host more than 15,000 attendees Rehovot, Israel, April 11, 2024 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a B2B provider of AI accelerated video solutions for edge platforms, today announced its participation in the upcoming Special Operations Forces (SOF) Week, which will take place from May 6 to May 9, 2024,in Tampa, Florida. The Company will demonstrate the capabilities of its innovative solutions with AI acceleration capabilities suitable for professional and tactical operations. Particularly, the Company will showcase its flagship product Jupiter AI, a high-end multiple-stream video platform that can be mounted on diverse autonomous platforms, as well as its Opal tactical edge computing...

The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 1/2a trial initiation. Additional financing also to support the Company’s oncology clinical program, with interim safety data readout in Q2 for its allogeneic product candidate. SANTA ANA, Calif., April 11, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has closed $5 million in second lien convertible loan funding with a term of 30 months, augmenting approximately $4.75 in gross cash proceeds from prior 2024 funding to date. Outstanding...

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities. Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma.WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) —  Tevogen Bio Holdings (Tevogen) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer, explains the company’s oncology pipeline strategy. “CTLs can be used for cancer treatments in several ways. Certain cancers are virally driven and can be targeted...

Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413)In accordance with the study protocol, the safety and efficacy topline analysis includes sequential organ failure assessment (SOFA) scores and mortality for the 28-day period post treatment. Efficacy:Stand-alone analysis of the Allocetra™-treated patients, of which 78% had septic shock and 65% had invasive ventilation at screening, demonstrated substantial reductions in SOFA scores and 65% reduction in overall mortality rate as compared with expected mortality2.  By day 28, the analysis showed 90% reductions of SOFA scores for sepsis patients whose infection source was urinary tract, 68% for patients whose infection source was community-acquired pneumonia, and 36% for patients whose infection source was internal abdominal infection. Relative analysis...